Sarepta Therapeutics said it would be delayed at least six months in seeking approval for its muscular-dystrophy drug after the FDA demanded more information because of concerns over the clinical-trial data.
from WSJ.com: US Business http://ift.tt/1wv5OB4
via IFTTT
from WSJ.com: US Business http://ift.tt/1wv5OB4
via IFTTT
No comments:
Post a Comment